GlassScriptPhysician profile
Roya Golshani
NPI 1033144522
$6,988.07
in general payments reported to CMS, 2019-2025
32 companies · $1,198 in 2025
The $1,198 reported for 2025 was more than what 87% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $786 · 2020: $134 · 2021: $774 · 2022: $1,204 · 2023: $1,167 · 2024: $1,724 · 2025: $1,198.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,090.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,089.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,935.50 | 2019-2025 | |
| Janssen Biotech, INC. | $993.49 | 2019-2025 | Stelara, Tremfya |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $940.54 | 2019-2023 | Xifaxan, Trulance |
| Qol Medical, LLC | $508.05 | 2020-2025 | Sucraid, Sucraid |
| Lilly USA, LLC | $294.82 | 2024-2025 | Omvoh, Zepbound, Mounjaro |
| Ardelyx, INC. | $285.87 | 2022-2025 | Ibsrela |
| Nestle Healthcare Nutrition INC. | $197.00 | 2021-2023 | |
| Phathom Pharmaceuticals, INC. | $192.15 | 2024-2025 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $170.79 | 2019-2025 | Entyvio |
| Regeneron Healthcare Solutions, INC. | $157.62 | 2024-2025 | Dupixent |
| Medtronic, INC. | $150.00 | 2023 | Cobalt Dr Mri Surescan |
| Novo Nordisk INC | $127.91 | 2021-2025 | Wegovy, Rybelsus, Ozempic |
| Ironwood Pharmaceuticals, INC | $113.91 | 2019-2024 | Linzess |
| Celltrion USA INC. | $105.71 | 2024-2025 | Vegzelma |
| Boston Scientific Corporation | $104.93 | 2019 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $100.11 | 2019-2024 | Tepezza, Repatha, Otezla |
| Aimmune Therapeutics, INC. | $93.96 | 2024 | |
| Ferring Pharmaceuticals INC. | $73.46 | 2019-2023 | Rebyota |
| Daiichi Sankyo INC. | $67.33 | 2019-2021 | |
| Abbott Laboratories | $46.81 | 2024 | Freestyle Libre 3 |
| Pfizer INC. | $45.48 | 2021-2023 | |
| Redhill Biopharma INC. | $41.98 | 2020-2021 | |
| Braintree Laboratories, INC. | $36.92 | 2019-2025 | Sutab |
| Novartis Pharmaceuticals Corporation | $26.62 | 2024 | |
| Organon LLC | $25.78 | 2023 | Hadlima |
| Intercept Pharmaceuticals, INC. | $25.01 | 2019 | |
| Evoke Pharma, INC. | $23.26 | 2023 | Gimoti |
| Celgene Corporation | $23.17 | 2021 | |
| Sun Pharmaceutical Industries INC. | $23.13 | 2021 | |
| Allergan, INC. | $20.86 | 2019 | |
| Exact Sciences Corporation | $19.92 | 2023 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $15.98 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roya Golshani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.